BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 23, 2006
View Archived Issues
SuperGen's $34M Sell-Off To Mayne Includes Nipent
In an effort to focus on its preclinical targeted therapeutics, SuperGen Inc. decided to sell the North American rights to Nipent and SurfaceSafe to Mayne Pharma Ltd. in a deal worth $34 million. (BioWorld Today)
Read More
XenoPort Offering: $76.5M For Transported Prodrugs
Read More
Supreme Court's Non-Ruling Seen As Friendly To Biotech
Read More
QuatRx Adds HSD Inhibitors To Endocrine Drug Pipeline
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Appointments And Advancements
Read More